Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2023-505605-16-00
2023-505605-16-00RecruitingPhase 2

Kidney cancer

Oncorena AB, Oncorena AB1 site in 1 country65 target enrollmentStarted: June 21, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
65
Locations
1
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Oncorena AB, Oncorena AB
Sponsor Class
Pharmaceutical company, Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Börje Haraldsson

Scientific

Oncorena AB

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Kidney Tumor Study München Klinik BogenhauseC64Malignant neoplasm of kidney, except renal pelvis
DRKS00034124Klinik für Urologie, München Klinik Bogenhausen gGmbH300
Not yet recruiting
Not Applicable
Mainz Kidney cancer observational Registry studyC64Malignant neoplasm of kidney, except renal pelvis
DRKS00034452niversitätsmedizin Mainz - Klinik und Poliklinik für Urologie und Kinderurologie800
Recruiting
Not Applicable
Kidney cancer treatment & outcome study.
CTRI/2012/11/003147Indian Cooperative Oncology Network100
Completed
Not Applicable
Detection of Urologic Cancers and Chronic Kidney Disease in Patients with COPDCOPD
JPRN-UMIN000017299Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital400
Not yet recruiting
Not Applicable
Study on the combined scheme of Quxie Capsule in the third-line treatment of metastatic colorectal cancer and the characteristics of the dominant populatiocolorectal cancer
ITMCTR2200006487XiyuanHospital of CACMS